[1] Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells[J]. Science, 1999, 284(5411): 143-147. [2] Jiang Y, Jahagirdar BN, Reinhardt RL, et al. Pluripotency of mesenchymal stem cells derived from adult marrow[J]. Nature, 2002, 418(6893): 41-49. 3] Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues [J]. Science, 1997, 276(5309): 71-74. [4] Schliephake H, Knebel W, Aufderheide M, et al. Use of cultivated osteoprogenitor cells to increase bone formation in segmental mandibular defects: an experimental pilot study in sheep [J]. Int J Oral Maxillofac Surg, 2001, 30(6): 531-537. [5] Riley EH, Lane JM, Urist MR, et al. Bone morphogenetic protein-2: biology and applications[J]. Clin Orthop Relat Res, 1996, (324): 39-46. [6] Heggebö J, Haasters F, Polzer H, et al. Aged human mesenchymal stem cells: the duration of bone morphogenetic protein-2 stimulation determines induction or inhibition of osteogenic differentiation[J]. Orthop Rev (Pavia), 2014, 6(2):5242. [7] Valentin-opran A, Wozney J, Csimma C. Clinical evaluation of recombinant human bone morphogenetic protein-2 [J]. Clin Orthop Relat Res, 2002, (395): 110-120. [8] Ulrich-Vinther M. Gene therapy methods in bone and joint disorders. Evaluation of the adeno-associated virus vector in experimental models of articular cartilage disorders, periprosthetic osteolysis and bone healing[J]. Acta Orthop Suppl, 2007, 78(325): 1-64. [9] Dai KR, Xu XL, Tang TT, et al. Repairing of goat tibial bone defects with BMP-2 gene-modified tissue-engineered bone [J]. Calcif Tissue Int, 2005, 77(1): 55-61. [10] Park J, Ries J, Gelse K, et al. Bone regeneration in critical size defects by cell-mediated BMP-2 gene transfer: a comparison of adenoviral vectors and liposomes[J]. Gene Ther, 2003, 10(13): 1089-1098. [11] Chang SC, Chuang H, Chen YR, et al. Cranial repair using BMP-2 gene engineered bone marrow stromal cells [J]. J Surg Res, 2004, 119(1): 85-91. [12] Jiang J, Huang L, Yu W, et a1. Overexpression of HTRA1 leads to down-regulation of fibronectin and functional changes in RF/6A cells and HUVECs [J]. PLoS One, 2012, 7(10): e461l5. [13] Cockrell AS, Kafri T. Gene delivery by lentivirus vectors [J].Mol Biotechnol, 2007, 36(3): 184-204. [14] D'Costa J, Mansfield SG, Humeau LM. Lentiviral vectors in clinical trials: current status[J]. Curr Opin Mol Ther, 2009, 11(5): 554-564. |